Prescribing information



Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1


Watch recordings from an event which took place on 1st July 2021, in which Dr Tracey Vell MBE, Dr Jaimini Cegla, and Dr Matt Kearney discuss a variety of topics including an overview of NHS England’s CVD agenda, the challenges faced in lipid management, an overview of the NHS England proposed programme to improve lipid management, including the implementation of inclisiran, and some of inclisiran’s clinical trial data.



Introduction to inclisiran

Watch Dr Jaimini Cegla provide an overview of key inclisiran product information, including safety and efficacy data from the Phase III ORION-10 and ORION-11 clinical trials.2


The proposed launch of inclisiran in England

Watch Dr Tracey Vell MBE discuss the current challenges that primary care faces in lipid management, as well as the introduction of inclisiran into the lipid pathway and the proposed role primary care could play in this.

At the time of recording, inclisiran was undergoing a NICE appraisal.


Cholesterol and cardiovascular disease management

Watch Dr Matt Kearney discuss why cholesterol and cardiovascular disease management is a key focus for NHS England right now.



Watch more inclisiran events and recordings


CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service


  1. Leqvio® Summary of Product Characteristics.
  2. Ray KK et al. N Engl J Med 2020;382(16):1507–1519.
Rate this content: 
No votes yet
UK | September 2021 | 152489

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]